Findings from 18-fluciclovine (Axumin) positron emission tomography/computed tomography imaging had a major impact on management decisions for men with biochemical recurrence of prostate cancer.
Cheryl Guttman Krader
Published findings from PROCEED, a large registry collecting data from men treated with sipuleucel-T (Provenge) for asymptomatic/minimally symptomatic metastatic castration-resistant prostate cancer, provide valuable insight on real-world outcomes associated with this immunotherapy agent in the modern era of prostate cancer management.
Sacral neuromodulation placement in a single-stage procedure is likely to be less costly than a two-stage approach for most practitioners, according to the findings of a cost minimization analysis.
Data from prospective clinical trials show that the efficacy of high-velocity waterjet ablation (Aquablation using the AquaBeam System) for improving BPH-related signs and symptoms is the same in patients with a large-to-very large prostate as in men with a small-to-moderate size gland, said Naeem Bhojani, MD, at the AUA annual meeting in Chicago.
The long-term durability of surgical modalities for management of BPH varies significantly, findings from a retrospective study suggest.
Analyses of data collected in PROCEED, a large real-world registry, corroborate phase III study findings demonstrating that sipuleucel-T (Provenge) treatment for metastatic castrate-resistant prostate cancer has a particular benefit for improving overall survival in African-American men.
Analyses based on number needed to treat benefit show that the overall survival benefit is similar when using abiraterone acetate (ZYTIGA), enzalutamide (XTANDI), or sipuleucel-T (Provenge) to treat men with chemotherapy-naïve metastatic castration-resistant prostate cancer. The data, however, favor sipuleucel-T for having the lowest direct cost.
“The variability in recommendations [for hematuria evaluation] and our study’s findings highlight implicit value judgments and a potentially high burden of harms not historically considered in many guidelines’ development process," says Matthew E. Nielsen, MD, MS.
A study evaluating outcomes of the prostatic urethral lift (PUL; UroLift System) in clinical practice show that the efficacy and safety documented in the selected group of men enrolled in clinical trials is maintained across the broader spectrum of patients who present for treatment of symptomatic BPH in the real-world setting.
Neoadjuvant chemohormonal therapy warrants consideration in the management of men undergoing radical prostatectomy for clinically localized high-risk prostate cancer, said James Eastham, MD, at the American Society of Clinical Oncology annual meeting in Chicago.